<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-6-64</article-id><article-id pub-id-type="pmid">16539695</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-64</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>CHEK2 </italic>1100delC in patients with metachronous cancers of the breast and the colorectum</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Isinger</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Anna.Isinger@med.lu.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bhat</surname><given-names>Misha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>teddyhome@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Borg</surname><given-names>Ake</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Ake.Borg@med.lu.se</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Nilbert</surname><given-names>Mef</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Mef.Nilbert@med.lu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Oncology, Institute of Clinical Sciences, Lund University, 221 85 Lund, Sweden</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>15</day><month>3</month><year>2006</year></pub-date><volume>6</volume><fpage>64</fpage><lpage>64</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/64"/><history><date date-type="received"><day>27</day><month>10</month><year>2005</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2006</year></date></history><copyright-statement>Copyright &#x000a9; 2006 Isinger et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>Development of multiple primary tumors is a hallmark of hereditary cancer. At least 1/10 of breast cancers and colorectal cancers occur because of heredity and recently the cell cycle kinase 2, <italic>CHEK2 </italic>1100delC allele has been identified at a particularly high frequency in families with hereditary breast and colorectal cancer.</p></sec><sec sec-type="methods"><title>Methods</title><p>We utilized the Southern Sweden population-based cancer registry to identify women with double primary breast and colorectal cancer and sequenced tumor material in order to assess the contribution of the <italic>CHEK2 </italic>1100delC to the development of such metachronous tumors.</p></sec><sec><title>Results</title><p>Among the 75 patients successfully analyzed, 2 (2.5%) carried the <italic>CHEK2 </italic>1100delC allele. which was not significantly different (p = 0.26) from the 1% (3/300) carriers identified in the control group.</p></sec><sec><title>Conclusion</title><p>In summary, our data suggest that the <italic>CHEK2 </italic>1100delC is not a major cause of double primary breast and colorectal cancer in Sweden, which suggests that this patient group should not routinely be screened for the <italic>CHEK2 </italic>1100delC variant.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>At least 10% of both breast cancers and colorectal cancers are estimated to develop because of heredity. The <italic>BRCA1 </italic>and <italic>BRCA2 </italic>genes are the major causes of hereditary breast and ovarian cancer, but the underlying genetic defect remains unresolved in the majority of the families with familial or hereditary breast cancer [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. In colorectal cancer, familial adenomatous polyposis due to mutations in <italic>APC </italic>and the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome caused by mutations in the mismatch-repair genes <italic>MLH1, MSH2, MSH6 </italic>and <italic>PMS2 </italic>are the underlying causes of many families with hereditary colorectal, whereas the genetic defects remains unknown in most of the families with hereditary colorectal cancer with higher age at onset and lack of other associated tumor types [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Searches for additional high-penetrant disease-causing genes in these cancer types have so far not been successful and it is likely that low-penetrant genetic variants may contribute a substantial fraction of hereditary breast cancer and colorectal cancer [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Double-strand DNA breaks lead to activation of the cell cycle checkpoint kinase 2, CHEK2 [GenBank:<ext-link ext-link-type="gen" xlink:href="AL121825">AL121825</ext-link>], through ATM phosphorylation [<xref ref-type="bibr" rid="B6">6</xref>]. CHEK2 plays an important role in cell cycle regulation and DNA damage repair, processes that are central in prevention of tumor development. The <italic>CHEK2 </italic>1100delC mutation leads to premature termination and abrogates kinase activity. This variant allele occurs in about 1% of normal populations, but has been identified at increased frequencies (1.2&#x02013;1.9%) in individuals with breast cancer [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. An approximately 2-fold increased risk of breast cancer has been associated with the <italic>CHEK2 </italic>1100delC mutation [<xref ref-type="bibr" rid="B8">8</xref>]. Higher frequencies, 5.1&#x02013;11.4%, of the <italic>CHEK2 </italic>1100delC allele have by some investigators been reported in non-<italic>BRCA1/2 </italic>families with hereditary breast cancer [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>], although other studies from e.g. Australia and Spain have not found an increased frequency in such families [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. These differences may be ascribed to geographical variations as well as to different sample sets, particularly regarding the number of family members affected, age at onset, and selection of e.g. families with male breast cancer. Since the <italic>CHEK2 </italic>1100delC variant does not show clear co-segregation with disease it is considered to be a modifier, and may act in cooperation with yet unidentified high-penetrance genes or together with multiple low-penetrant genes as part of polygenic inheritance.</p><p>In studies from Finland and the Netherlands the <italic>CHEK2 </italic>1100delC has been reported at frequencies of 1.6&#x02013;2.6% among individuals with colorectal cancer, which is not significantly higher than in unaffected individuals from the population, but these studies may be compatible with a risk of 1.5&#x02013;2.0 for development of colorectal cancer among carriers [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. A particularly high frequency of the <italic>CHEK2 </italic>1100delC allele has been reported in families with hereditary breast and colorectal cancer where 10/55 Dutch families (18%) carried the mutation [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Since development of multiple primary tumors in an individual is a sign of hereditary cancer we utilized a population-based cancer registry to identify women who had developed breast cancer and colorectal cancer in order to assess the contribution of the <italic>CHEK2 </italic>1100delC mutation to the development of metachronous cancers of these types.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient material</title><p>Ethical approval was obtained from the ethics committee at the Lund University. We utilized the population-based cancer registry of the Southern swedish health care region (which currently has approximately 1.7 million inhabitants). The registry was established in 1958 and because of mandatory cancer registration for clinicians as well as for pathologists the registry is estimated to contain 98% of all cancers diagnosed in this area. All females diagnosed with at least one breast cancer and one colorectal cancer during the time period 1958&#x02013;2000 were identified. Totally 96 patients were identified in whom breast cancer was the first tumor in 64 and colorectal cancer was the first tumor in 25, whereas the remaining 7 patients developed synchronous breast and colorectal cancer. The mean age at diagnosis of the first of tumor was 68 (range 40&#x02013;95) years, breast cancer developed at mean age 70 (range 40&#x02013;95) and colorectal cancer at age 74 (range 47&#x02013;98). After omission of patients who were misclassified or from whom the tumor blocks could not be retrieved, 84 patients remained for analysis.</p><p>Tumor-containing paraffin-embedded tissue and normal tissue (e.g. resection borders or benign lymph nodes) were retrieved. Fresh sections were obtained and stained with Hematoxylin &#x00026; Erythrosin in order to verify that tumor tissue was present in the samples. DNA was extracted from 3 &#x000d7; 10 &#x003bc;m paraffin sections using treatment with Proteinase K in 65&#x000b0;C for at least 2 hours and boiled for 10 minutes for enzyme inactivation, whereafter the samples were centrifuged and the aqueous phase was removed for use.</p></sec><sec><title>dHPLC and sequencing</title><p>Mutation analysis was carried out using dHPLC (Transgenomic WAVE Nucleic Acid Fragment Analyzer System Model 3500HT) and samples with aberrant patterns were further analyzed by direct sequencing (Terminator Cycle Sequencing Reaction Kits version 3.1, ABI Prism 3100 Genetic Analyzer; Applied Biosystems). Due to homologous sequences primer design is complex for <italic>CHEK2 </italic>exon 10. The primers used were 5'-TGGCAAGTTCAACATTATTCCC-3' (forward) [<xref ref-type="bibr" rid="B17">17</xref>] and 5'-ATCACCTCCTACCAGTCTGTGC-3' (reverse) [<xref ref-type="bibr" rid="B10">10</xref>]. PCR amplification was performed in a final volume of 25 &#x003bc;l containing: 2.5 &#x003bc;l 10 &#x000d7; PCR buffer, 2&#x02013;3 &#x003bc;l MgCl (25 mM), 0.5 &#x003bc;l dNTP (20 mM), 0.7 &#x003bc;l primer (10 &#x003bc;M) and 0.1 &#x003bc;l polymerase. PCR conditions are available from the authors upon request. Heteroduplex formation was performed by mixing tumor DNA with wild-type DNA, heating to 94&#x000b0;C and lowering the temperature by 1&#x000b0;C per minute until 45&#x000b0;C was reached.</p></sec></sec><sec><title>Results</title><p>Of the 84 patients, 75 (89%) were successfully analyzed. In total, 36 breast cancers and 67 colorectal cancers were analyzed and from 34 patients normal tissue was also analyzed. The majority of the patients developed breast cancer as their first tumor (table <xref ref-type="table" rid="T1">1</xref>) and 68 of the patients developed other malignant tumors, most commonly malignant melanoma (n = 18), endometrial cancer (n = 12) and urinary bladder cancer (n = 6). The <italic>CHEK2 </italic>1100delC mutation was detected in 2 patients (2.5%) (table <xref ref-type="table" rid="T2">2</xref>). Both the breast cancer and the colorectal cancer was analyzed and found to carry the mutation in these cases and, in case 17 the mutation was verified also in normal tissue. Chromatograms over the results are shown in figure <xref ref-type="fig" rid="F1">1</xref>.</p><p>In order to determine the expected frequency of the <italic>CHEK2 </italic>1100delC in the Southern swedish population dHPLC analysis and direct sequencing was performed from 300 healthy individuals with identification of the variant allele in 3/300 individuals, thus at a population frequency of 1% [<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Discussion</title><p>A subtype of familial breast cancer that includes colorectal cancer was recognized by Lynch <italic>et al</italic>. already in 1972 [<xref ref-type="bibr" rid="B19">19</xref>] and recently the <italic>CHEK2 </italic>1100delC mutation was proposed to represent a low-penetrant breast cancer susceptibility allele [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. This variant has been identified at a particularly high frequency (18%) in families with a hereditary breast- and colorectal cancer phenotype [<xref ref-type="bibr" rid="B16">16</xref>]. Since development of multiple primary tumors is a hallmark of hereditary cancer and a high frequency of the <italic>CHEK2 </italic>1100delC had been described in hereditary breast and colorectal families, we assessed the contribution of this variant to the development of double primary breast and colorectal cancer in a population-based patient material. Among the 75 patients with metachronous tumors of the breast and the colorectum successfully studied, 2 (2.5%) carried the <italic>CHEK2 </italic>1100delC mutation compared to 1% in the control group [<xref ref-type="bibr" rid="B18">18</xref>]. These frequencies were not significantly different (p = 0.26), but the small size of the population-based patient material limits the strength of this comparison. However, the low frequency of this alteration in our material implies that development of metachronous breast cancer and colorectal cancer in women is <italic>per se </italic>not alone to identify individuals with a high likelihood of being carriers of the <italic>CHEK2 </italic>1100delC mutation. Although development of double primary tumors may be a sign of heredity it is not enough to recommend genetic analysis, though the family history of cancer should be carefully reviewed. Our findings are in line with previous studies that exclude <italic>CHEK2 </italic>1100delC as a major contributor to the breast and colorectal cancer phenotype [<xref ref-type="bibr" rid="B16">16</xref>]. Huang <italic>et al</italic>. [<xref ref-type="bibr" rid="B20">20</xref>] did not identify any <italic>CHEK2 </italic>1100delC mutation among 24 patients from the US with breast cancer and colorectal cancer. Also, in the study by Meijers-Heijboer <italic>et al</italic>. that primarily identified the link between <italic>CHEK2 </italic>1100delC and familial breast and colorectal cancer in Dutch families, the vast majority, 45/55 families, who fulfilled these criteria did indeed not carry this variant [<xref ref-type="bibr" rid="B16">16</xref>]. However geographical differences may influence the importance of the <italic>CHEK </italic>1100delC mutation.</p><p>Among the two women with the <italic>CHEK2 </italic>1100delC allele in our study, one presented with two separate, synchronous, breast cancers. An increased risk of multiple primary breast cancers (OR 5.7&#x02013;6.5) has been reported in individuals carrying this <italic>CHEK2 </italic>1100delC allele [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. However, the <italic>CHEK2 </italic>1100delC mutation has not only been suggested to act as a low-penetrant susceptibility gene in breast cancer families, but the <italic>CHEK2 </italic>I157T alteration has been proposed to act as a multiorgan cancer susceptibility allele based on observations of an increased risk for development of breast cancer, colon cancer, prostate cancer, thyroid cancer, and renal cancer in Polish families [<xref ref-type="bibr" rid="B23">23</xref>]. Both patients in our study, did in addition to breast cancer and colorectal cancer, develop a third tumor, two renal cancers at ages 49 and 73 (table <xref ref-type="table" rid="T2">2</xref>). In the Swedish cancer registry 8&#x02013;10% of the patients develop 2 or more malignancies (The Board of Social Health and Welfare, Cancer Incidence in Sweden 2003). The development of renal cancer in two of our patients was intriguing in relation to Cybulski <italic>et al</italic>. who identified an increased risk of renal cancer associated with <italic>CHEK2</italic>, albeit in carriers of the <italic>CHEK2 </italic>I157T variant [<xref ref-type="bibr" rid="B23">23</xref>]. However, since our study was registry-based no data on additional cancer cases in these families are available.</p></sec><sec><title>Conclusion</title><p>In summary, our findings demonstrate that the <italic>CHEK2 </italic>1100delC occurs at a low frequency in Swedish women with double primary breast cancer and colorectal cancer, and thus suggests that development of these two tumor types is not sufficient to recommend mutation analysis of <italic>CHEK2</italic>.</p></sec><sec><title>Conflict of interest statement</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AI conceived of the study, performed the sequencing analysis, interpret data and drafted the manuscript. MB also carried out the sequencing. AB participated in its design and helped to draft the manuscript. MN conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/64/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank Eva Rambech and Kristina L&#x000f6;vgren for technical assistance.</p><p>The Swedish Cancer Society, the Nilsson Cancer Research Foundation, the Kamprad Research Foundation, the Gustaf V Foundation, and the Lund University Hospital Cancer Funds financially supported this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Swensen</surname><given-names>J</given-names></name><name><surname>Shattuck-Eidens</surname><given-names>D</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Harshman</surname><given-names>K</given-names></name><name><surname>Tavtigian</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Cochran</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Rosenthal</surname><given-names>J</given-names></name><name><surname>Hussey</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>McClure</surname><given-names>M</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Hattier</surname><given-names>T</given-names></name><name><surname>Phelps</surname><given-names>R</given-names></name><name><surname>Haugen-Strano</surname><given-names>A</given-names></name><name><surname>Katcher</surname><given-names>H</given-names></name><name><surname>Yakumo</surname><given-names>K</given-names></name><name><surname>Gholami</surname><given-names>Z</given-names></name><name><surname>Shaffer</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>S</given-names></name><name><surname>Bayer</surname><given-names>S</given-names></name><name><surname>Wray</surname><given-names>C</given-names></name><name><surname>Bogden</surname><given-names>R</given-names></name><name><surname>Dayananth</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Bristow</surname><given-names>PK</given-names></name><name><surname>Norris</surname><given-names>FH</given-names></name><name><surname>Helvering</surname><given-names>L</given-names></name><name><surname>Morrison</surname><given-names>P</given-names></name><name><surname>Rosteck</surname><given-names>P</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Lewis</surname><given-names>C</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Cannon-Albright</surname><given-names>L</given-names></name><name><surname>Goldgar</surname><given-names>D</given-names></name><name><surname>Wiseman</surname><given-names>R</given-names></name><name><surname>Kamb</surname><given-names>A</given-names></name><name><surname>Skolnick</surname><given-names>MH</given-names></name></person-group><article-title>A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1</article-title><source>Science</source><year>1994</year><volume>266</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7545954</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Lancaster</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Micklem</surname><given-names>G</given-names></name></person-group><article-title>Identification of the breast cancer susceptibility gene BRCA2</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>789</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">8524414</pub-id><pub-id pub-id-type="doi">10.1038/378789a0</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de la Chapelle</surname><given-names>A</given-names></name></person-group><article-title>Genetic predisposition to colorectal cancer</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">15510158</pub-id><pub-id pub-id-type="doi">10.1038/nrc1453</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peltomaki</surname><given-names>P</given-names></name><name><surname>Vasen</surname><given-names>H</given-names></name></person-group><article-title>Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database</article-title><source>Dis Markers</source><year>2004</year><volume>20</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">15528792</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balmain</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>J</given-names></name><name><surname>Ponder</surname><given-names>B</given-names></name></person-group><article-title>The genetics and genomics of cancer</article-title><source>Nat Genet</source><year>2003</year><volume>33 Suppl</volume><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">12610533</pub-id><pub-id pub-id-type="doi">10.1038/ng1107</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartek</surname><given-names>J</given-names></name><name><surname>Falck</surname><given-names>J</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name></person-group><article-title>CHK2 kinase--a busy messenger</article-title><source>Nat Rev Mol Cell Biol</source><year>2001</year><volume>2</volume><fpage>877</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">11733767</pub-id><pub-id pub-id-type="doi">10.1038/35103059</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedrichsen</surname><given-names>DM</given-names></name><name><surname>Malone</surname><given-names>KE</given-names></name><name><surname>Doody</surname><given-names>DR</given-names></name><name><surname>Daling</surname><given-names>JR</given-names></name><name><surname>Ostrander</surname><given-names>EA</given-names></name></person-group><article-title>Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><fpage>R629</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15535844</pub-id><pub-id pub-id-type="doi">10.1186/bcr933</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><article-title>CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>1175</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">15122511</pub-id><pub-id pub-id-type="doi">10.1086/421251</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>RA</given-names></name><name><surname>Kroeze-Jansema</surname><given-names>K</given-names></name><name><surname>Kraan</surname><given-names>J</given-names></name><name><surname>Morreau</surname><given-names>H</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name><name><surname>Hoogerbrugge</surname><given-names>N</given-names></name><name><surname>Ligtenberg</surname><given-names>MJ</given-names></name><name><surname>van Asperen</surname><given-names>CJ</given-names></name><name><surname>Vasen</surname><given-names>HF</given-names></name><name><surname>Meijers</surname><given-names>C</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>de Bock</surname><given-names>TH</given-names></name><name><surname>Cornelisse</surname><given-names>CJ</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name></person-group><article-title>The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>8153</fpage><lpage>8157</lpage><pub-id pub-id-type="pmid">14678969</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>van den Ouweland</surname><given-names>A</given-names></name><name><surname>Klijn</surname><given-names>J</given-names></name><name><surname>Wasielewski</surname><given-names>M</given-names></name><name><surname>de Snoo</surname><given-names>A</given-names></name><name><surname>Oldenburg</surname><given-names>R</given-names></name><name><surname>Hollestelle</surname><given-names>A</given-names></name><name><surname>Houben</surname><given-names>M</given-names></name><name><surname>Crepin</surname><given-names>E</given-names></name><name><surname>van Veghel-Plandsoen</surname><given-names>M</given-names></name><name><surname>Elstrodt</surname><given-names>F</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Bartels</surname><given-names>C</given-names></name><name><surname>Meijers</surname><given-names>C</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>McGuffog</surname><given-names>L</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>D</given-names></name><name><surname>Sodha</surname><given-names>N</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Barfoot</surname><given-names>R</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Eccles</surname><given-names>D</given-names></name><name><surname>Eeles</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name><name><surname>Murday</surname><given-names>V</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Peretz</surname><given-names>T</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>HX</given-names></name><name><surname>Szabo</surname><given-names>C</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Goldgar</surname><given-names>D</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><article-title>Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations</article-title><source>Nat Genet</source><year>2002</year><volume>31</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">11967536</pub-id><pub-id pub-id-type="doi">10.1038/ng879</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vahteristo</surname><given-names>P</given-names></name><name><surname>Bartkova</surname><given-names>J</given-names></name><name><surname>Eerola</surname><given-names>H</given-names></name><name><surname>Syrjakoski</surname><given-names>K</given-names></name><name><surname>Ojala</surname><given-names>S</given-names></name><name><surname>Kilpivaara</surname><given-names>O</given-names></name><name><surname>Tamminen</surname><given-names>A</given-names></name><name><surname>Kononen</surname><given-names>J</given-names></name><name><surname>Aittomaki</surname><given-names>K</given-names></name><name><surname>Heikkila</surname><given-names>P</given-names></name><name><surname>Holli</surname><given-names>K</given-names></name><name><surname>Blomqvist</surname><given-names>C</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name></person-group><article-title>A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer</article-title><source>Am J Hum Genet</source><year>2002</year><volume>71</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">12094328</pub-id><pub-id pub-id-type="doi">10.1086/341943</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jekimovs</surname><given-names>CR</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Arnold</surname><given-names>J</given-names></name><name><surname>Gatei</surname><given-names>M</given-names></name><name><surname>Richard</surname><given-names>DJ</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Khanna</surname><given-names>KK</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name></person-group><article-title>Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals</article-title><source>Br J Cancer</source><year>2005</year><volume>92</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">15700044</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6602381</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osorio</surname><given-names>A</given-names></name><name><surname>Rodriguez-Lopez</surname><given-names>R</given-names></name><name><surname>Diez</surname><given-names>O</given-names></name><name><surname>de la Hoya</surname><given-names>M</given-names></name><name><surname>Ignacio Martinez</surname><given-names>J</given-names></name><name><surname>Vega</surname><given-names>A</given-names></name><name><surname>Esteban-Cardenosa</surname><given-names>E</given-names></name><name><surname>Alonso</surname><given-names>C</given-names></name><name><surname>Caldes</surname><given-names>T</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name></person-group><article-title>The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population</article-title><source>Int J Cancer</source><year>2004</year><volume>108</volume><fpage>54</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">14618615</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11414</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>MM</given-names></name><name><surname>Nolte</surname><given-names>IM</given-names></name><name><surname>Te Meerman</surname><given-names>GJ</given-names></name><name><surname>van der Graaf</surname><given-names>WT</given-names></name><name><surname>Mulder</surname><given-names>MJ</given-names></name><name><surname>van der Steege</surname><given-names>G</given-names></name><name><surname>Bruinenberg</surname><given-names>M</given-names></name><name><surname>Schaapveld</surname><given-names>M</given-names></name><name><surname>Niessen</surname><given-names>RC</given-names></name><name><surname>Berends</surname><given-names>MJ</given-names></name><name><surname>Sijmons</surname><given-names>RH</given-names></name><name><surname>Hofstra</surname><given-names>RM</given-names></name><name><surname>de Vries</surname><given-names>EG</given-names></name><name><surname>Kleibeuker</surname><given-names>JH</given-names></name></person-group><article-title>Colorectal cancer and the CHEK2 1100delC mutation</article-title><source>Genes Chromosomes Cancer</source><year>2005</year><pub-id pub-id-type="pmid">15852425</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kilpivaara</surname><given-names>O</given-names></name><name><surname>Laiho</surname><given-names>P</given-names></name><name><surname>Aaltonen</surname><given-names>LA</given-names></name><name><surname>Nevanlinna</surname><given-names>H</given-names></name></person-group><article-title>CHEK2 1100delC and colorectal cancer</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>e110</fpage><pub-id pub-id-type="pmid">14569133</pub-id><pub-id pub-id-type="doi">10.1136/jmg.40.10.e110</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>Wijnen</surname><given-names>J</given-names></name><name><surname>Vasen</surname><given-names>H</given-names></name><name><surname>Wasielewski</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Hollestelle</surname><given-names>A</given-names></name><name><surname>Elstrodt</surname><given-names>F</given-names></name><name><surname>van den Bos</surname><given-names>R</given-names></name><name><surname>de Snoo</surname><given-names>A</given-names></name><name><surname>Fat</surname><given-names>GT</given-names></name><name><surname>Brekelmans</surname><given-names>C</given-names></name><name><surname>Jagmohan</surname><given-names>S</given-names></name><name><surname>Franken</surname><given-names>P</given-names></name><name><surname>Verkuijlen</surname><given-names>P</given-names></name><name><surname>van den Ouweland</surname><given-names>A</given-names></name><name><surname>Chapman</surname><given-names>P</given-names></name><name><surname>Tops</surname><given-names>C</given-names></name><name><surname>Moslein</surname><given-names>G</given-names></name><name><surname>Burn</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>H</given-names></name><name><surname>Klijn</surname><given-names>J</given-names></name><name><surname>Fodde</surname><given-names>R</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name></person-group><article-title>The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype</article-title><source>Am J Hum Genet</source><year>2003</year><volume>72</volume><fpage>1308</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">12690581</pub-id><pub-id pub-id-type="doi">10.1086/375121</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Pierce</surname><given-names>H</given-names></name><name><surname>Kirchhoff</surname><given-names>T</given-names></name><name><surname>Kolachana</surname><given-names>P</given-names></name><name><surname>Rapaport</surname><given-names>B</given-names></name><name><surname>Gregersen</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Yossepowitch</surname><given-names>O</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Satagopan</surname><given-names>J</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Scheuer</surname><given-names>L</given-names></name><name><surname>Nafa</surname><given-names>K</given-names></name><name><surname>Ellis</surname><given-names>N</given-names></name></person-group><article-title>Frequency of CHEK2*1100delC in New York breast cancer cases and controls</article-title><source>BMC Med Genet</source><year>2003</year><volume>4</volume><fpage>1</fpage><pub-id pub-id-type="pmid">12529183</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-4-1</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagenius</surname><given-names>M</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Giwercman</surname><given-names>A</given-names></name><name><surname>Bratt</surname><given-names>O</given-names></name></person-group><article-title>CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden</article-title><source>Scand J Urol Nephrol</source><year>2006</year><volume>40</volume><fpage>23</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16452051</pub-id><pub-id pub-id-type="doi">10.1080/00365590500368518</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Krush</surname><given-names>AJ</given-names></name><name><surname>Lemon</surname><given-names>HM</given-names></name><name><surname>Kaplan</surname><given-names>AR</given-names></name><name><surname>Condit</surname><given-names>PT</given-names></name><name><surname>Bottomley</surname><given-names>RH</given-names></name></person-group><article-title>Tumor variation in families with breast cancer</article-title><source>Jama</source><year>1972</year><volume>222</volume><fpage>1631</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">4678365</pub-id><pub-id pub-id-type="doi">10.1001/jama.222.13.1631</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Domchek</surname><given-names>SM</given-names></name><name><surname>Brose</surname><given-names>MS</given-names></name><name><surname>Rebbeck</surname><given-names>TR</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name></person-group><article-title>Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>e120</fpage><pub-id pub-id-type="pmid">15520402</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.022913</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>de Witte</surname><given-names>L</given-names></name><name><surname>Nooijen</surname><given-names>A</given-names></name><name><surname>Huseinovic</surname><given-names>A</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name><name><surname>van Leeuwen</surname><given-names>FE</given-names></name><name><surname>Russell</surname><given-names>NS</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name></person-group><article-title>Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers</article-title><source>Breast Cancer Res Treat</source><year>2004</year><volume>83</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">14997059</pub-id><pub-id pub-id-type="doi">10.1023/B:BREA.0000010697.49896.03</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname><given-names>GH</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Krol-Warmerdam</surname><given-names>EM</given-names></name><name><surname>Seynaeve</surname><given-names>C</given-names></name><name><surname>Blom</surname><given-names>J</given-names></name><name><surname>Brekelmans</surname><given-names>CT</given-names></name><name><surname>Meijers-Heijboer</surname><given-names>H</given-names></name><name><surname>van Asperen</surname><given-names>CJ</given-names></name><name><surname>Cornelisse</surname><given-names>CJ</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Tollenaar</surname><given-names>RA</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name></person-group><article-title>Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><fpage>731</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">15466005</pub-id><pub-id pub-id-type="doi">10.1136/jmg.2004.019737</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cybulski</surname><given-names>C</given-names></name><name><surname>Gorski</surname><given-names>B</given-names></name><name><surname>Huzarski</surname><given-names>T</given-names></name><name><surname>Masojc</surname><given-names>B</given-names></name><name><surname>Mierzejewski</surname><given-names>M</given-names></name><name><surname>Debniak</surname><given-names>T</given-names></name><name><surname>Teodorczyk</surname><given-names>U</given-names></name><name><surname>Byrski</surname><given-names>T</given-names></name><name><surname>Gronwald</surname><given-names>J</given-names></name><name><surname>Matyjasik</surname><given-names>J</given-names></name><name><surname>Zlowocka</surname><given-names>E</given-names></name><name><surname>Lenner</surname><given-names>M</given-names></name><name><surname>Grabowska</surname><given-names>E</given-names></name><name><surname>Nej</surname><given-names>K</given-names></name><name><surname>Castaneda</surname><given-names>J</given-names></name><name><surname>Medrek</surname><given-names>K</given-names></name><name><surname>Szymanska</surname><given-names>A</given-names></name><name><surname>Szymanska</surname><given-names>J</given-names></name><name><surname>Kurzawski</surname><given-names>G</given-names></name><name><surname>Suchy</surname><given-names>J</given-names></name><name><surname>Oszurek</surname><given-names>O</given-names></name><name><surname>Witek</surname><given-names>A</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Lubinski</surname><given-names>J</given-names></name></person-group><article-title>CHEK2 is a multiorgan cancer susceptibility gene</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><fpage>1131</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">15492928</pub-id><pub-id pub-id-type="doi">10.1086/426403</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>dHPLC and reverse sequence results that demonstrate the <italic>CHEK2 </italic>1100delC variant in the two patients. Both patients were heterozygous mutation carriers. The heteroduplex formations are seen as extra peaks in the dHPLC chromatogram.</p></caption><graphic xlink:href="1471-2407-6-64-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical data in the cohort analyzed (n = 75).</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Tumor type</bold></td><td align="center"><bold>Mean age (range) at diagnosis (years)</bold></td></tr></thead><tbody><tr><td align="left">Breast cancer</td><td align="center">70 (40&#x02013;94)</td></tr><tr><td align="left">Colorectal cancer</td><td align="center">74 (47&#x02013;92)</td></tr><tr><td align="left">Age at first cancer</td><td align="center">68 (40&#x02013;90)</td></tr><tr><td align="left">Breast cancer as first cancer (n = 50)</td><td align="center">68 (40&#x02013;93)</td></tr><tr><td align="left">Colorectal cancer as first cancer (n = 20)</td><td align="center">70 (48&#x02013;85)</td></tr><tr><td align="left">Synchronous breast and colorectal cancer (n = 5)</td><td align="center">70 (47&#x02013;82)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Clinical data from the two individuals carrying the <italic>CHEK2 </italic>1100delC mutation.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Patient</bold></td><td align="center"><bold>Cancer type</bold></td><td align="center"><bold>Age (years)</bold></td></tr></thead><tbody><tr><td align="left">B17</td><td align="center">Rectal cancer</td><td align="center">69</td></tr><tr><td></td><td align="center">Renal cancer</td><td align="center">73</td></tr><tr><td></td><td align="center">Breast cancer</td><td align="center">74</td></tr><tr><td align="left">B79</td><td align="center">Synchronous breast cancer</td><td align="center">47</td></tr><tr><td></td><td align="center">Colon cancer</td><td align="center">48</td></tr><tr><td></td><td align="center">Renal cancer</td><td align="center">49</td></tr></tbody></table></table-wrap></sec></back></article> 